Anti-cytomegalovirus effects of tricin are dependent on CXCL11

Microbes and Infection

Volumn 14, Issue 12, 2012, Pages 1086-1092

  Murayama, Tsugiya ^a,d   Li, Ying ^a,b   Takahashi, Takashi ^c   Yamada, Rie ^a   Matsubara, Keiko ^a   Tuchida, Yuuzo ^b   Li, Zhuan ^a   Sadanari, Hidetaka ^a  

^a HOKURIKU UNIVERSITY   (Japan)

^b Hououdou Co Ltd   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti cytomegalovirus activity; Chemokine; CXCL11; SiRNA; Tricin

Indexed keywords

4',5,7 TRIHYDROXY 3',5' DIMETHOXYFLAVONE; ANTIVIRUS AGENT; CHEMOATTRACTANT; CXCL11 CHEMOKINE; INTERFERON; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOMEGALOVIRUS INFECTION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; CHEMOKINE CXCL11; CYTOMEGALOVIRUS; FIBROBLASTS; FLAVONOIDS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE KNOCKOUT TECHNIQUES; HUMANS; PLANT EXTRACTS; SASA; VIRUS REPLICATION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; SASA;

EID: 84866329165     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2012.05.017     Document Type: Article

References (38)

1. Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr. Top. Microbiol. Immunol. 2008, 325:417-470.
2. Dollard S.C., Grosse S.D., Ross D.S. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev. Med. Virol. 2007, 17:355-363.
3. Adler S.P., Nigro G., Pereira L. Recent advances in the prevention and treatment of congenital cytomegalovirus infections. Semin. Perinatol. 2007, 31:10-18.
4. Sissons J.G., Carmichael A.J. Clinical aspects and management of cytomegalovirus infection. J. Infect. 2002, 44:78-83.
5. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antivir. Res. 2006, 71:154-163.
6. Freitas V.R., Fraser-Smith E.B., Matthews T.R. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antivir. Res. 1989, 12:205-212.
7. Noble S., Faulds D. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 1998, 56:115-146.
8. Deray G., Martinez F., Katlama C., Levaltier B., Beaufils H., Danis M., Rozenheim M., Baumelou A., Dohin E., Gentilini M. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am. J. Nephrol. 1989, 9:316-321.
9. Ho E.S., Lin D.C., Mendel D.B., Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. 2000, 11:383-393.
10. Buerger I., Reefschlaeger J., Bender W., Eckenberg P., Popp A., Weber O., Graeper S., Klenk H.D., Ruebsamen-Waigmann H., Hallenberger S. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 2001, 75:9077-9086.
11. Yukawa T.A., Kurokawa M., Sato H., Yoshida Y., Kageyama S., Hasegawa T., Namba T., Imakita M., Hozumi T., Shiraki K. Prophylactic treatment of cytomegalovirus infection with traditional herbs. Antivir. Res. 1996, 32:63-70.
12. McSharry J.J., McDonough A., Olson B., Talarico C., Davis M., Biron K.K. Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin. Diagn. Lab. Immunol. 2001, 8:1279-1281.
13. Schroer J., Shenk T. Inhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus. Proc. Natl. Acad. Sci. USA 2008, 105:19468-19473.
14. Biron K.K., Harvey R.J., Chamberlain S.C., Good S.S., Smith A.A., Davis M.G., Talarico C.L., Miller W.H., Ferris R., Dornsife R.E., Stanat S.C., Drach J.C., Townsend L.B., Koszalka G.W. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 2002, 46:2365-2372.
15. Lischka P., Zimmermann H. Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr. Opin. Pharmacol. 2008, 8:541-548.
16. Lischka P., Hewlett G., Wunberg T., Baumeister J., Paulsen D., Goldner T., Ruebsamen-Schaeff H., Zimmermann H. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob. Agents Chemother. 2010, 54:1290-1297.
17. Moutaftsi M., Brennan P., Spector S.A., Tabi Z. Impaired lymphoid chemokine-mediated migration due to a block on the chemokine receptor switch in human cytomegalovirus-infected dendritic cells. J. Virol. 2004, 78:3046-3054.
18. Prechtel A.T., Turza N.M., Kobelt D.J., Eisemann J.I., Coffin R.S., McGrath Y., Hacker C., Ju X., Zenke M., Steinkasserer A. Infection of mature dendritic cells with herpes simplex virus type 1 dramatically reduces lymphoid chemokine-mediated migration. J. Gen. Virol. 2005, 86:1645-1657.
19. Varani S., Frascaroli G., Homman-Loudiyi M., Feld S., Landini M.P., Soderberg-Naucler C. Human cytomegalovirus inhibits the migration of immature dendritic cells by down-regulating cell-surface CCR1 and CCR5. J. Leukoc. Biol. 2005, 77:219-228.
20. Salentin R., Gemsa D., Sprenger H., Kaufmann A. Chemokine receptor expression and chemotactic responsiveness of human monocytes after influenza A virus infection. J. Leukoc. Biol. 2003, 74:252-259.
21. Abt M., Gassert E., Schneider-Schaulies S. Measles virus modulates chemokine release and chemotactic responses of dendritic cells. J. Gen. Virol. 2009, 90:909-914.
22. Zeremski M., Dimova R., Brown Q., Jacobson I.M., Markatou M., Talal A.H. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J. Infect. Dis. 2009, 200:1774-1780.
23. Sakai A., Watanabe K., Koketsu M., Akuzawa K., Yamada R., Li Z., Sadanari H., Matsubara K., Muroyama T. Anti-human cytomegalovirus activity of constituents from Sasa albo-marginata (Kumazasa in Japan). Antivir. Chem. Chemother. 2008, 19:125-132.
24. Akuzawa K., Yamada R., Li Z., Li Y., Sadanari H., Matsubara K., Watanabe K., Koketsu M., Tuchida Y., Murayama T. Inhibitory effects of tricin derivative from Sasa albo-marginata on replication of human cytomegalovirus. Antivir. Res. 2011, 91:296-303.
25. Jassim S.A., Naji M.A. Novel antiviral agents: a medicinal plant perspective. J. Appl. Microbiol. 2003, 95:412-427.
26. Jacobs J.P., Jones C.M., Baille J.P. Characteristics of a human diploid cell designated MRC-5. Nature 1970, 227:168-170.
27. Furukawa T., Fioretti A., Plotkin S. Growth characteristics of cytomegalovirus in human fibroblasts with demonstration of protein synthesis early in viral replication. J. Virol. 1973, 11:991-997.
28. Wentworth B.B., French L. Plaque assay of cytomegalovirus strains of human origin. Proc. Soc. Exp. Biol. Med. 1970, 135:253-258.
29. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993, 15:532-534. 536-537.
30. Ogawa N., Kawanami T., Shimoyama K., Ping L., Sugai S. Expression of interferon-inducible T cell alpha chemoattractant (CXCL11) in the salivary glands of patients with Sjogren's syndrome. Clin. Immunol. 2004, 112:235-238.
31. Nishiwaki M., Fujimuro M., Teishikata Y., Inoue H., Sasajima H., Nakaso K., Nakashima K., Sadanari H., Yamamoto T., Fujiwara Y., Ogawa N., Yokosawa H. Epidemiology of Epstein-Barr virus, cytomegalovirus, and Kaposi's sarcoma-associated herpesvirus infections in peripheral blood leukocytes revealed by a multiplex PCR assay. J. Med. Virol. 2006, 78:1635-1642.
32. Petrik D.T., Schmitt K.P., Stinski M.F. Inhibition of cellular DNA synthesis by the human cytomegalovirus IE86 protein is necessary for efficient virus replication. J. Virol. 2006, 80:3872-3883.
33. Yamakawa J., Ishigaki Y., Takano F., Takahashi T., Yoshida J., Moriya J., Takata T., Tatsuno T., Sasaki K., Ohta T., Takegami T., Yoshizaki F. The Kampo medicines Orengedokuto, Bofutsushosan and Boiogito have different activities to regulate gene expressions in differentiated rat white adipocytes: comprehensive analysis of genetic profiles. Biol. Pharm. Bull. 2008, 31:2083-2089.
34. Loetscher M., Gerber B., Loetscher P., Jones S.A., Piali L., Clark-Lewis I., Baggiolini M., Moser B. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 1996, 184:963-969.
35. Hirota Y., Osuga Y., Koga K., Yoshino O., Hirata T., Morimoto C., Harada M., Takemura Y., Nose E., Yano T., Tsutsumi O., Taketani Y. The expression and possible roles of chemokine CXCL11 and its receptor CXCR3 in the human endometrium. J. Immunol. 2006, 177:8813-8821.
36. De Clercq E. New inhibitors of human cytomegalovirus (HCMV) on the horizon. J. Antimicrob. Chemother. 2003, 51:1079-1083.
37. Scholz M., Doerr H.W., Cinatl J. Inhibition of cytomegalovirus immediate early gene expression: a therapeutic option?. Antivir. Res. 2001, 49:129-145.
38. Murayama T., Mukaida N., Sadanari H., Yamaguchi N., Khabar K.S., Tanaka J., Matsushima K., Mori S., Eizuru Y. The immediate early gene 1 product of human cytomegalovirus is sufficient for up-regulation of interleukin-8 gene expression. Biochem. Biophys. Res. Commun. 2000, 279:298-304.